BeiGene
.png){kind=logo} | |
| Company type | Public |
|---|---|
| Founded | 2010 in Beijing, China |
| Founder |
|
| Website | beigene |
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. It was founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler.
History
BeiGene was founded in late 2010 by Xiaodong Wang, a Chinese-American scientist, and John V. Oyler,[1] an American entrepreneur who serves as the company's chief executive officer and chairman.[2] While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs take place elsewhere. Wang and Oyler envisioned creating a biopharmaceutical company with strong ties to China to conduct research and development.[1][3] They chose to focus specifically on cancer treatment. By July 2011, they had recruited more than 60 Chinese scientists, including 20 who were US-educated. The founders provided part of the initial seed money and also received early backing from the American pharmaceutical company Merck & Co.[1]
References
- ^ a b c Loo, Daryl (2011-07-07). "BeiGene Brings Biotech to China". Bloomberg. Retrieved 2020-08-04.
{{cite web}}: CS1 maint: url-status (link) - ^ Lovelace, Berkeley, Jr (2019-10-31). "Amgen takes 20% stake in Chinese biotech BeiGene for $2.7 billion". CNBC. Retrieved 2020-08-04.
{{cite web}}: CS1 maint: multiple names: authors list (link) CS1 maint: url-status (link) - ^ Wright, Rob (2019-11-01). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 2020-08-04.
{{cite web}}: CS1 maint: url-status (link)